ライフサイエンスコーパス: coronary

1 Specifically, coronary (18)F-fluoride uptake had a high signal to nois

2 Total coronary (18)F-NaF uptake was determined by the coronary

3 resentation, low use of invasive procedures, coronary access issues) and were associated with a poor

4 o ameliorate chronic allograft rejection and coronary allograft vasculopathy.

5 Patients undergoing emergent coronary angiogram were included.

6 tal during 1986-2015 with at least 1 post-HT coronary angiogram.

7 CAV was present in 17 (46.0%) reference coronary angiograms, at a median of 1.9 years before CCT

8 ocol-based monitoring consisting of repeated coronary angiographies together with systematic assessme

9 nary angiography (78.3% versus 81.4%), early coronary angiography (49.2% versus 54.1%), percutaneous

10 3% versus 35.7%), and received less-frequent coronary angiography (78.3% versus 81.4%), early coronar

11 thin 12 h) or standard (48 to 72 h) invasive coronary angiography (ICA).

12 AR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac

13 y, NIRS was performed in patients undergoing coronary angiography and possible percutaneous coronary

14 h an initial invasive strategy consisting of coronary angiography and revascularization (if appropria

15 T) Program to analyze patients who underwent coronary angiography between January 1, 2009, and Septem

16 ious clinical trials, does not support early coronary angiography for comatose survivors of cardiac a

17 use of coronary physiology as an adjunct to coronary angiography to guide percutaneous coronary inte

18 hest pain with troponin elevation and normal coronary angiography) occurred in 15% of patients with D

19 was first manifestation of CAV diagnosed by coronary angiography.

20 Forty-nine patients were randomized to early coronary angiography.

21 In cultured coronary arterial smooth muscle cells (CASMCs) from Asah

22 Myocardial infarction with nonobstructive coronary arteries (MINOCA) occurs in 6% to 15% of myocar

23 condition is remodelling of intramural small coronary arteries and arterioles.

24 cular mechanisms underlying the formation of coronary arteries during development and during cardiac

25 O (Global Use of Strategies to Open Occluded Coronary Arteries) severe/life-threatening/moderate and

26 data on intravascular lithotripsy use in the coronary arteries, and future directions for adoption of

27 though fat while acutely sparing nearby the coronary arteries.

28 d at 90 to 100 W for 4 minutes at sites near coronary arteries.

29 he highest doses of exercise training on the coronary arteries.

30 was correlated with desmosine (p<0.001), and coronary artery (p=0.002) and thoracic aortic (p<0.001)

31 ith endothelial dysfunction in patients with coronary artery and/or cardiovascular disease.

32 redominantly afflicts young children, causes coronary artery aneurysms and can result in long-term ca

33 sease in developed nations and can result in coronary artery aneurysms and death.

34 Coronary artery aneurysms develop in some untreated chil

35 isk score, coronary artery calcium score, or coronary artery area stenosis.

36 mic vascular disease that included aorta and coronary artery atheroma, cardiac hypertensive disease,

37 ery followed by the left anterior descending coronary artery branch.

38 his study is to compare HCR and conventional coronary artery bypass graft (CABG) surgery medium-term

39 tio, 0.68 [95% CI, 0.59-0.79]; P<0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95%

40 y (1.85; 95% CI, 1.33-2.58) and lowest after coronary artery bypass grafting + mitral valve surgery (

41 us Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated wh

42 eficiaries who underwent elective colectomy, coronary artery bypass grafting, abdominal aortic aneury

43 their performance to predict adjudicated non-coronary artery bypass grafting-related GUSTO (Global Us

44 YNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narr

45 dial infarction without procedure] to 55.3% [coronary artery bypass surgery only]).

46 Patients without AF undergoing coronary artery bypass surgery were recruited.

47 acute myocardial infarction hospitalization; coronary artery bypass surgery; heart valve repair/repla

48 ate analysis identified donor age >40 years, coronary artery bypass, and no aspirin after LT as indep

49 extent, defined by a combined metric of the coronary artery calcification score and 2-dimensional va

50 ardiac maladaptations, including accelerated coronary artery calcification, exercise-induced cardiac

51 ing Research) with long-term follow-up after coronary artery calcium measurement.

52 ntify carotid and femoral plaque volume; and coronary artery calcium score (CACS) at baseline and 2.8

53 EAT measures were compared to coronary artery calcium score and atherosclerotic cardio

54 Herein, we review the use of the coronary artery calcium score as a decision aid in indiv

55 , irrespective of cardiovascular risk score, coronary artery calcium score, or coronary artery area s

56 olled phase 2b trial compared progression of coronary artery calcium volume score and other measureme

57 The primary end point was change in log coronary artery calcium volume score from baseline to we

58 The mean change in coronary artery calcium volume score was 11% (95% CI, 7-

59 ly 1 case in the MIS-C group (4%) manifested coronary artery dilatation (z score = 3.15) in the acute

60 rdiac arrhythmias, pericardial effusion, and coronary artery dilatation.

61 95% confidence interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those wit

62 The most common cause of SCD was coronary artery disease (40%), followed by sudden arrhyt

63 Coronary artery disease (CAD) causes mortality and morbi

64 Coronary artery disease (CAD) is a major cause of morbid

65 Coronary artery disease (CAD) is more frequent among ind

66 in the circulation of patients with unstable coronary artery disease (CAD), and their recruitment to

67 ch demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or r

68 variables for inferring risk factors causing coronary artery disease (CAD).

69 erved to improve the health of patients with coronary artery disease (CAD).

70 on clinical read and no known macrovascular coronary artery disease (n=783), MPR remained independen

71 s ratio, 4.22 [95% CI, 1.71-10.4], P=0.002), coronary artery disease (odds ratio, 0.35 [95% CI, 0.16-

72 nfidence interval (CI), 1.2-3.4, P = 0.009), coronary artery disease (OR, 1.9; 95% CI, 1.1-3.7; P = 0

73 32 145 patients: 14 095 (43.8%) with stable coronary artery disease and 18 046 (56.1%) with acute co

74 dial infarction in patients with established coronary artery disease are lacking.

75 We included 13 patients with coronary artery disease due to severe atherosclerosis an

76 The poorer prognosis of coronary artery disease in females compared with males i

77 cardial ischaemia resulting from obstructive coronary artery disease is a major cause of morbidity an

78 Coronary artery disease is the main cause of burden of d

79 Patients with established coronary artery disease or peripheral artery disease oft

80 i-tissue gene expression associations to key coronary artery disease processes and clinical phenotype

81 litus and hypertension to slow and stabilize coronary artery disease progression and improve clinical

82 ients with de novo 3-vessel and/or left main coronary artery disease randomized to treatment with PCI

83 In the Coronary Artery Disease Risk Development in Young Adults

84 d phenotypic modulation of this cell type in coronary artery disease risk.

85 Participants with stable coronary artery disease underwent acute mental stress te

86 Background Progression of coronary artery disease using serial coronary computed t

87 the use of paclitaxel DCBs for treatment of coronary artery disease was not associated with increase

88 , ST-segment elevation, and absence of known coronary artery disease were independent predictors of u

89 acute myocardial infarction and multivessel coronary artery disease were randomly assigned to one of

90 In patients with established coronary artery disease, (18)F-NaF PET provides powerful

91 e by age 75 years ranged from 17% to 78% for coronary artery disease, 13% to 76% for breast cancer, a

92 That coronary artery disease, but not chronic lung disease, w

93 In the absence of obstructive coronary artery disease, intravascular imaging technique

94 has been shown that in patients with chronic coronary artery disease, ischemic episodes lead to a glo

95 therapy is secondary prevention, concomitant coronary artery disease, particularly with prior myocard

96 In the absence of epicardial coronary artery disease, patients with heart transplants

97 In revascularisation of left main coronary artery disease, PCI was associated with an infe

98 Among patients with coronary artery disease, statin medication rates increas

99 investigating the effects of prediabetes in coronary artery disease, stroke and chronic kidney disea

100 mong patients with angina and nonobstructive coronary artery disease, those with coronary microvascul

101 n diet reduces the incidence and severity of coronary artery disease, whereas supplementation with ni

102 erotic cardiovascular disease-in particular, coronary artery disease-and its contribution to disease

103 anisms, further establishing a role for this coronary artery disease-associated gene in fundamental S

104 Residential remoteness was associated with coronary artery disease-related SCD (odds ratio, 1.44 [9

105 rtality at 10 years in patients with complex coronary artery disease.

106 -related biomarkers with type 2 diabetes and coronary artery disease.

107 n humans, TCF21 expression inhibits risk for coronary artery disease.

108 rely performed for patients with multivessel coronary artery disease.

109 larisation strategy in patients with complex coronary artery disease.

110 ray of applications beyond the assessment of coronary artery disease.

111 or the treatment of hypercholesterolemia and coronary artery disease.

112 traditional risk factors of atherosclerotic coronary artery disease.

113 d atheroprotective marker, in particular for coronary artery disease; however, HDL particle concentra

114 Over the past decade, spontaneous coronary artery dissection (SCAD) has emerged as an impo

115 Spontaneous coronary artery dissection (SCAD) is a non-atherosclerot

116 Intraseptal anomalous aortic origin of a coronary artery is considered a benign condition.

117 9) underwent left anterior descending (LAD) coronary artery ligation to mimic vulnerable atheroscler

118 ramagnetic shift associated with duration of coronary artery occlusion and the presence of iron.

119 mmon, occurring even in the absence of acute coronary artery occlusion, and contributes to high rates

120 Acute occlusion of a coronary artery results in swift tissue necrosis.

121 This study analyzed data from the CARDIA (Coronary Artery Risk Development in Young Adults Study).

122 uded 191 participants from the CARDIA study (Coronary Artery Risk Development in Young Adults), a com

123 In this ex vivo imaging study of coronary artery specimens, the non-invasive imaging radi

124 phy angiography (CTA) may be used to exclude coronary artery stenosis >=50% in patients with NSTEACS.

125 was the ability of coronary CTA to rule out coronary artery stenosis (>=50% stenosis) in the entire

126 Coronary artery stenosis is a narrowing of coronary lume

127 luzole died from ischaemic heart disease and coronary artery thrombosis, and one patient assigned flu

128 e rejection (>1 y) have been associated with coronary artery vasculopathy (CAV) in pediatric heart tr

129 Changes in coronary artery, thoracic aorta, and cardiac valve calci

130 c_0001445 levels were associated with higher coronary atherosclerosis extent and severity with a 2-fo

131 f physical activity and exercise training on coronary atherosclerosis in athletes who are middle-aged

132 ine N-oxide (TMAO), has been associated with coronary atherosclerotic burden.

133 s a non-invasive imaging biomarker of active coronary atherosclerotic mineralisation.

134 curate and reproducible 3D reconstruction of coronary bifurcations.

135 Resting coronary blood flow (CBF) (24.6 +/- 2.0 cm/s vs. 16.6 +/

136 lity failed to deliver effective guidance of coronary bypass surgery to a reduction of adverse cardia

137 cedural myocardial infarction and 1 emergent coronary bypass.

138 Coronary calcification hinders stent delivery and expans

139 acute coronary syndrome admitted to Swedish coronary care units.

140 with suspected stable CAD who had undergone coronary computed tomographic angiography (CTA).

141 sion of coronary artery disease using serial coronary computed tomography angiography (CTA) is of cli

142 The purpose of this study was to test if coronary computed tomography angiography (CTA) may be us

143 c naive psoriasis patients (n=209) underwent coronary computed tomography angiography at baseline and

144 g further supportive evidence for the use of coronary CT angiography as the first-line test for the e

145 Key coronary CT angiography studies have included rigorous m

146 The primary endpoint was the ability of coronary CTA to rule out coronary artery stenosis (>=50%

147 component of the trial, a clinically blinded coronary CTA was conducted prior to ICA in both groups.

148 The CORonary Diet Intervention with Olive oil and cardiovasc

149 hies/Congenital & Genetics, Cardio-Oncology, Coronary Disease & Interventions, Hypertension, Imaging,

150 invasive or conservative strategy for stable coronary disease.

151 ne the difference between MEndoT-derived and coronary endothelial cells is essential for understandin

152 r future research into the use of CT-FFR for coronary evaluation pre-aortic valve replacement.

153 associated risk was only observed for major coronary events (1.64 [1.35, 2.00]) and ischemic stroke

154 ascular events (MVEs), including 7,326 major coronary events (MCEs), 37,992 ischemic heart disease (I

155 r vascular events (P(trend)=0.005) and major coronary events (P(trend)<0.0001).

156 ex quintile were 2.15 [1.72, 2.69] for major coronary events, 1.65 [1.50, 1.80] for ischemic stroke,

157 23- and 1.65-fold increased hazard for major coronary events, respectively.

158 nts (including myocardial infarctions, fatal coronary events, silent infarctions, revascularization p

159 While comorbidity between coronary heart disease (CHD) and depression is evident,

160 otein(a) (Lp[a]) and family history (FHx) of coronary heart disease (CHD) are individually associated

161 d 15,837 incident CVD cases, including 9,794 coronary heart disease (CHD) cases and 6,174 strokes.

162 Rates for recurrent coronary heart disease (CHD) events have declined in the

163 zed, single-blind, controlled trial in 1,002 coronary heart disease (CHD) patients, whose primary obj

164 Periodontal disease has been linked to coronary heart disease (CHD), but studies have been inco

165 Diabetes mellitus is a major risk factor for coronary heart disease (CHD).

166 Circulating lipoprotein lipids cause coronary heart disease (CHD).

167 was associated with a lower risk of incident coronary heart disease among participants with the Hp2-2

168 n for the management of patients with stable coronary heart disease and discuss implications for the

169 In UK Biobank, a combination of coronary heart disease and heart failure in addition to

170 ar events in ambulatory patients with stable coronary heart disease and may merit routine use.

171 ex and is associated with polygenic risk for coronary heart disease and type 2 diabetes.

172 ion Trial to show a significant reduction in coronary heart disease or total mortality to the design

173 isease after menopause and typically develop coronary heart disease several years later than men.

174 , they also proposed an alternative: whether coronary heart disease was preventable at all by simulta

175 2 diabetes, inflammatory bowel disease, and coronary heart disease, all of which have available earl

176 eclassification improvements for early-onset coronary heart disease, atrial fibrillation and prostate

177 idence interval, 8.38 to 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

178 ling was used to determine hazard ratios for coronary heart disease, CVD, and all-cause mortality acc

179 South Asian populations including premature coronary heart disease, early type 2 diabetes mellitus,

180 k for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibril

181 rbanization level, hyperlipidemia, diabetes, coronary heart disease, migraine, hypotension, and obstr

182 own to play a key role in the development of Coronary Heart Disease.

183 ical functioning, diabetes, hypertension, or coronary heart disease.

184 ke or transient ischemic attack and no known coronary heart disease.

185 influence of a modern lifestyle in abetting Coronary Heart Diseases (CHD) have mostly focused on det

186 ins that may serve as risk factors for human coronary heart diseases.

187 than control immediately after percutaneous coronary intervention (14.1+/-4.1% versus 12.0+/-3.3%; P

188 giography (49.2% versus 54.1%), percutaneous coronary intervention (59.2% versus 64.0%), and mechanic

189 ent ethyl significantly reduced percutaneous coronary intervention (hazard ratio, 0.68 [95% CI, 0.59-

190 (HR, 0.72 [95% CI, 0.59-0.90]), percutaneous coronary intervention (HR, 0.78 [95% CI, 0.63-0.95]), an

191 outcomes of patients undergoing percutaneous coronary intervention (PCI) for ISR in the United States

192 Undergoing percutaneous coronary intervention (PCI) is a risk factor for AKI dev

193 atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear.

194 onship has not been studied for percutaneous coronary intervention (PCI) of chronic total occlusion (

195 mpared with aspirin alone after percutaneous coronary intervention (PCI) or acute coronary syndrome b

196 levation myocardial infarction, percutaneous coronary intervention (PCI) reduces mortality when compa

197 ospitals in patients undergoing percutaneous coronary intervention (PCI) treated with MCS (Impella or

198 e (VCD) are thought to mitigate percutaneous coronary intervention (PCI)-related bleeding.

199 th CA among patients undergoing percutaneous coronary intervention (PCI).

200 ronary angiography and possible percutaneous coronary intervention (PCI).

201 fter unprotected left main stem percutaneous coronary intervention (uLMS-PCI) is poorly defined.

202 ated this evolving physiological guidance of coronary intervention and its use is supported by large

203 dual antiplatelet therapy after percutaneous coronary intervention and the withholding of aspirin amo

204 s in timely delivery of primary percutaneous coronary intervention are expected, a modern fibrinolyti

205 to perform expeditious primary percutaneous coronary intervention for patients presenting with ST-se

206 igh-risk patients after primary percutaneous coronary intervention for ST-segment-elevation myocardia

207 y syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban th

208 risk (HBR) patients undergoing percutaneous coronary intervention have been widely excluded from ran

209 ly versus immediate multivessel percutaneous coronary intervention in patients presenting with acute

210 r an acute coronary syndrome or percutaneous coronary intervention in patients with atrial fibrillati

211 hemic and bleeding events after percutaneous coronary intervention in the GLOBAL LEADERS study.

212 ting intravascular imaging with percutaneous coronary intervention may overcome the barriers to utili

213 cularization strategies: either percutaneous coronary intervention of the culprit-lesion-only or imme

214 ntrol (50 patients treated with percutaneous coronary intervention only).

215 -hospital transfers for primary percutaneous coronary intervention that reflects inter-facility commu

216 ocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of dista

217 , and had higher AMI volume and percutaneous coronary intervention use during the AMI hospitalization

218 The clinical success of percutaneous coronary intervention was 97.9%.

219 ere assessed and compared after percutaneous coronary intervention with bare-metal stents (BMS) and f

220 py reduces major bleeding after percutaneous coronary intervention with drug-eluting stents, whereas

221 ded-term (>12-month) DAPT after percutaneous coronary intervention with drug-eluting stents.

222 eated with sonothrombolysis and percutaneous coronary intervention) or control (50 patients treated w

223 Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillatio

224 CE after revascularization with percutaneous coronary intervention, even with contemporary DES.

225 At the time of percutaneous coronary intervention, participants were randomly assign

226 n-only or immediate multivessel percutaneous coronary intervention.

227 12 inhibitors in patients after percutaneous coronary intervention.

228 ine cardiac catheterization and percutaneous coronary intervention.

229 trategy from medical therapy to percutaneous coronary intervention.

230 5% among patients who underwent percutaneous coronary intervention.

231 l infarction undergoing primary percutaneous coronary intervention.

232 mpared to immediate multivessel percutaneous coronary intervention.

233 or adoption of the technique in percutaneous coronary intervention.

234 iplatelet prescribing following percutaneous coronary intervention.The primary outcome was the rate o

235 heart valve repair/replacement; percutaneous coronary intervention; or heart/heart-lung transplant).

236 diographic monitoring following percutaneous coronary interventions (PCI) is not well studied.

237 o coronary angiography to guide percutaneous coronary interventions has accumulated over the past 25

238 After adjustment, PCI of unstable coronary lesions was independently associated with impro

239 CL316,243 or ASP9531, starting 2 weeks after coronary ligation.

240 Coronary artery stenosis is a narrowing of coronary lumen space caused by an atherosclerotic lesion

241 s uncover a SHF vasculogenic contribution to coronary lymphatic development through a local niche at

242 onary (18)F-NaF uptake was determined by the coronary microcalcification activity (CMA).

243 tructive coronary artery disease, those with coronary microvascular dysfunction have a poor outcome.

244 maging and analysis toolset to visualize the coronary microvasculature in intact embryonic hearts and

245 yocardium that makes it feasible to identify coronary mineralisation activity.

246 contractility and relaxation while restoring coronary perfusion pressure.

247 Evidence supporting the use of coronary physiology as an adjunct to coronary angiograph

248 -10 was also inversely associated with total coronary plaque (rho = -0.19; P = .02) and noncalcified

249 aque (rho = -0.19; P = .02) and noncalcified coronary plaque (rho = -0.24; P = .004).

250 iated with increased prevalence of high-risk coronary plaque and risk of cardiovascular events.

251 accuracy, prognostic implications of adverse coronary plaque features, and sex differences.

252 hydroxyapatite deposition in atherosclerotic coronary plaque.

253 intracoronary alteplase infused early after coronary reperfusion associates with ischemic time.

254 increasing use and success of interventional coronary reperfusion strategies, morbidity and mortality

255 e, defined as the time from symptom onset to coronary reperfusion, was a pre-specified subgroup of in

256 or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L reduction in LD

257 Hybrid coronary revascularization (HCR) combines both.

258 /CT, identifies patients unlikely to undergo coronary revascularization within 90 days of a PET/CT.

259 I, recurrent CHD events (ie, recurrent MI or coronary revascularization), heart failure hospitalizati

260 cardiovascular death, myocardial infarction, coronary revascularization, and stroke through December

261 e stenosis is located in proximal and middle coronary segments and the FFR value is close to the cuto

262 Lead placement via the coronary sinus is the mainstay approach of cardiac resyn

263 for diagnosis of hemodynamically significant coronary stenosis was 98% and 96% respectively, compared

264 n of Fractional Flow Reserve in Intermediate Coronary Stenosis With Guiding Catheter Disengagement) r

265 logists to accurately assess the severity of coronary stenosis without resorting to invasive techniqu

266 h a low body weight presenting with an acute coronary syndrome (ACS) are unknown.

267 Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-in

268 T, a prospective multicenter cohort of acute coronary syndrome (ACS), in relation to BB use: prior to

269 common etiology of cardiac arrest was acute coronary syndrome (n = 1,657, 50% of reported).

270 04]; P=0.11); non-ST-segment-elevation acute coronary syndrome (RR, 0.84 [95% CI, 0.72-0.97]; P=0.02)

271 thresholds, in patients with suspected acute coronary syndrome admitted to Swedish coronary care unit

272 elevated risk for recurrent MACE after acute coronary syndrome and a larger absolute and relative ris

273 were associated with increased odds of acute coronary syndrome and its manifestations in individuals

274 with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coro

275 Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervent

276 taneous coronary intervention (PCI) or acute coronary syndrome but with increased risk of bleeding.

277 Incident acute coronary syndrome cases (N=167) were individually matche

278 tal admissions in England for types of acute coronary syndrome from Jan 1, 2019, to May 24, 2020, tha

279 nducted in 18 924 patients with recent acute coronary syndrome on intensive or maximum-tolerated stat

280 uration of the use of aspirin after an acute coronary syndrome or percutaneous coronary intervention

281 patients with non-ST-segment elevation acute coronary syndrome undergoing invasive treatment.

282 Patients With Non-ST-Segment Elevation Acute Coronary Syndrome) trial.

283 on of Cardiovascular Outcomes After an Acute Coronary Syndrome), which was conducted in 18 924 patien

284 es the risk of PAD events or VTE after acute coronary syndrome, and if such effects are related to le

285 death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revascularisation

286 artery disease and 18 046 (56.1%) with acute coronary syndrome.

287 l infarction of unknown type, or other acute coronary syndromes (including unstable angina).

288 esenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) in the EARLY ACS (Early Gly

289 iac arrhythmias, heart failure, and nonfatal coronary syndromes are also common.

290 ) Receptor Blockers In Non-ST Elevated Acute Coronary Syndromes With Initial Invasive Indication [DUB

291 mputerized Tomography in Patients With Acute Coronary Syndromes) trial (NCT02061891) evaluated the ou

292 e Optimal Strategy to Medically Manage Acute Coronary Syndromes) was a double-blind, placebo-controll

293 myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestina

294 f considering SCAD among patients with acute coronary syndromes.

295 tithrombotic Regimen: Rapid Early Action for Coronary Treatment 5).

296 on of CT FFR values, and color coding of the coronary tree according to CT FFR.

297 sing of CT data included segmentation of the coronary tree and heart contours, calculation of CT FFR

298 fy proangiogenic apelin as a key mediator of coronary vascular repair and a pharmacotherapeutic targe

299 tic target for immune-mediated injury of the coronary vasculature.

300 s a critical regulator for the remodeling of coronary vessels in the developing heart.